
Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, & Forecasts, 2025
Description
EXECUTIVE SUMMARY:
Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been undertaken. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.
Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
Cellular Therapy: iPSCs are being investigated for use in a wide range of cell therapy applications aimed at reversing injuries or curing diseases by replacing damaged or lost cells.
Disease Modeling: iPSCs derived from patients with specific disorders can be differentiated into disease-specific cell types, enabling the creation of accurate, functional disease models "in a dish" for research and therapeutic development.
Drug Development and Discovery: iPSCs provide physiologically relevant cells for drug discovery processes, including compound identification, target validation, compound screening, and tool development, significantly improving the efficiency and relevance of these efforts.
Personalized Medicine: By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, paving the way for customized treatments tailored to individual genetic profiles.
Toxicology Testing: iPSCs or their derivatives (tissue-specific cells) are used for toxicology screening to assess the safety and efficacy of compounds or drugs in living cells, reducing reliance on animal testing.
Tissue Engineering: iPSCs can be cultured on biocompatible scaffolds that mimic the structure and properties of target tissues, providing a supportive environment for cell growth and differentiation and aiding the development of engineered tissues for transplantation.
Organoid Production: iPSCs can self-organize into 3D structures called organoids, which closely resemble the structure and function of human organs. Organoids are valuable for studying organ development, modeling diseases, and testing drug candidates.
Gene Editing: iPSCs can be modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic alterations. These edited iPSCs can then be differentiated into functional cells for transplantation or advanced disease studies.
Research Tools: iPSCs and their derivatives are extensively used in both basic and applied research to study cellular processes, understand diseases, and test experimental therapies.
Stem Cell Banking: iPSC repositories store and provide access to diverse iPSC-derived cell types, offering researchers valuable resources to investigate conditions using cells from both healthy and affected donors.
Cultured Meat Production: iPSCs are utilized in lab-grown meat production, serving as a cellular foundation for creating clean, sustainable meat products without the need for traditional animal farming.
3D Bioprinting: iPSCs can be differentiated into specific cell types, such as skin, heart, or liver cells, and incorporated into bioinks for use in 3D bioprinting applications, enabling the creation of complex tissue structures.
iPSC Market Dynamics
Since the discovery of iPSCs approximately 18 years ago, the field has advanced at an unprecedented pace. It took just seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been increasingly used in preclinical studies, physician-led research, and clinical trials worldwide, underscoring their transformative potential.
The discovery of iPSCs has revolutionized several scientific fields, including drug discovery, toxicity testing, and in-a-dish disease modeling, while also having a profound impact on cell and gene therapy. Their ability to multiply indefinitely in vitro and differentiate into specialized cells has made them a highly versatile and ideal source for clinical cell replacement therapies and advanced disease modeling.
The first cellular therapy involving iPSCs began in 2013 at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, this trial investigated the safety of iPSC-derived retinal cell sheets in patients with macular degeneration. In 2016, Cynata Therapeutics achieved a world first by gaining approval for a clinical trial of an allogeneic iPSC-derived cell product, CYP-001, for treating steroid-resistant acute graft-versus-host disease (GvHD). This iPSC-derived mesenchymal stem cell (MSC) product demonstrated positive safety and efficacy results, successfully meeting its clinical endpoints.
Today, iPSCs are at the center of at least 155 ongoing clinical trials targeting a range of conditions. iPSC-derived MSCs are being tested for steroid-resistant acute GvHD, while dopaminergic progenitors derived from iPSCs are being evaluated for Parkinson’s disease. In oncology, iPSC-derived natural killer (iNK) cells are being studied as cancer immunotherapies for metastatic solid tumors. Other applications include the use of retinal pigment epithelial cells for age-related macular degeneration (AMD) and insulin-secreting beta cells derived from iPSCs for Type 1 diabetes. These diverse therapeutic programs highlight the vast potential of iPSCs in treating a variety of diseases.
The commercial potential of iPSCs has also expanded significantly. Companies are leveraging iPSC-derived products in drug development, disease modeling, and toxicology testing. FUJIFILM Cellular Dynamics International (FCDI) stands out as one of the largest players in the field. Cellular Dynamics International (CDI), founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, became one of the first companies to derive human iPSC lines in 2007. In 2015, FUJIFILM acquired CDI for $307 million, creating FCDI, which is now the world’s largest producer of human cells derived from iPSCs for research and regenerative medicine.
ReproCELL, founded in 2009 as a venture from the University of Tokyo and Kyoto University, was the first company to commercialize iPSC products. Its ReproCardio line of iPSC-derived cardiomyocytes paved the way for the industry. In Europe, leading competitors include Evotec and Ncardia. Evotec, based in Hamburg, Germany, has built one of the most advanced iPSC platforms in the world, focusing on industrializing iPSC-based drug screening. Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017, specializes in cardiac and neural applications of iPSCs. Axiogenesis, one of its predecessors, was the first European company to license iPSC technology in 2010.
Large research supply companies are also playing a major role in the commercialization of iPSC-derived products. These include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and numerous others. Collectively, more than 90 companies are active in the iPSC market, offering a broad range of products, services, and technologies that cater to both research and therapeutic applications.
The global iPSC market continues to grow rapidly. A comprehensive report on the field provides an overview of key players, strategic partnerships, and innovations driving the sector. The report explores the current status of iPSC research, manufacturing technologies, and clinical developments. It highlights the rates of iPSC-related patents, publications, and trials, detailing all known therapeutic programs involving iPSC-derived cells. Additionally, the report covers the funding landscape, examining fundraising efforts, IPOs, and co-development agreements that are shaping the market’s trajectory.
The report also delves into the expanding use of iPSCs in drug discovery and the strategic partnerships that are driving growth in this sector. It presents a detailed breakdown of market size by application, technology, cell type, and geography (North America, Europe, Asia-Pacific, and the rest of the world). Total market size figures, along with projected growth rates through 2030, provide insights into the future of the iPSC industry.
With their remarkable versatility, iPSCs are set to redefine medicine and biotechnology. From disease modeling and drug discovery to advanced cell replacement therapies, iPSCs are driving innovation at every level. As companies continue to refine manufacturing technologies and expand therapeutic applications, the future of iPSCs holds immense promise for transforming healthcare and scientific research.
About the Publisher
With an online readership of nearly one million viewers per year, the publisher is a U.S. market research firm with over 18 years of experience. As the first and only market research firm to specialize in the stem cell industry, the publisher’s research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, the publisher is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, the publisher has unparalleled access to key opinion leaders (KOLs) from across the global iPSC market.
Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been undertaken. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.
Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
Cellular Therapy: iPSCs are being investigated for use in a wide range of cell therapy applications aimed at reversing injuries or curing diseases by replacing damaged or lost cells.
Disease Modeling: iPSCs derived from patients with specific disorders can be differentiated into disease-specific cell types, enabling the creation of accurate, functional disease models "in a dish" for research and therapeutic development.
Drug Development and Discovery: iPSCs provide physiologically relevant cells for drug discovery processes, including compound identification, target validation, compound screening, and tool development, significantly improving the efficiency and relevance of these efforts.
Personalized Medicine: By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, paving the way for customized treatments tailored to individual genetic profiles.
Toxicology Testing: iPSCs or their derivatives (tissue-specific cells) are used for toxicology screening to assess the safety and efficacy of compounds or drugs in living cells, reducing reliance on animal testing.
Tissue Engineering: iPSCs can be cultured on biocompatible scaffolds that mimic the structure and properties of target tissues, providing a supportive environment for cell growth and differentiation and aiding the development of engineered tissues for transplantation.
Organoid Production: iPSCs can self-organize into 3D structures called organoids, which closely resemble the structure and function of human organs. Organoids are valuable for studying organ development, modeling diseases, and testing drug candidates.
Gene Editing: iPSCs can be modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic alterations. These edited iPSCs can then be differentiated into functional cells for transplantation or advanced disease studies.
Research Tools: iPSCs and their derivatives are extensively used in both basic and applied research to study cellular processes, understand diseases, and test experimental therapies.
Stem Cell Banking: iPSC repositories store and provide access to diverse iPSC-derived cell types, offering researchers valuable resources to investigate conditions using cells from both healthy and affected donors.
Cultured Meat Production: iPSCs are utilized in lab-grown meat production, serving as a cellular foundation for creating clean, sustainable meat products without the need for traditional animal farming.
3D Bioprinting: iPSCs can be differentiated into specific cell types, such as skin, heart, or liver cells, and incorporated into bioinks for use in 3D bioprinting applications, enabling the creation of complex tissue structures.
iPSC Market Dynamics
Since the discovery of iPSCs approximately 18 years ago, the field has advanced at an unprecedented pace. It took just seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been increasingly used in preclinical studies, physician-led research, and clinical trials worldwide, underscoring their transformative potential.
The discovery of iPSCs has revolutionized several scientific fields, including drug discovery, toxicity testing, and in-a-dish disease modeling, while also having a profound impact on cell and gene therapy. Their ability to multiply indefinitely in vitro and differentiate into specialized cells has made them a highly versatile and ideal source for clinical cell replacement therapies and advanced disease modeling.
The first cellular therapy involving iPSCs began in 2013 at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, this trial investigated the safety of iPSC-derived retinal cell sheets in patients with macular degeneration. In 2016, Cynata Therapeutics achieved a world first by gaining approval for a clinical trial of an allogeneic iPSC-derived cell product, CYP-001, for treating steroid-resistant acute graft-versus-host disease (GvHD). This iPSC-derived mesenchymal stem cell (MSC) product demonstrated positive safety and efficacy results, successfully meeting its clinical endpoints.
Today, iPSCs are at the center of at least 155 ongoing clinical trials targeting a range of conditions. iPSC-derived MSCs are being tested for steroid-resistant acute GvHD, while dopaminergic progenitors derived from iPSCs are being evaluated for Parkinson’s disease. In oncology, iPSC-derived natural killer (iNK) cells are being studied as cancer immunotherapies for metastatic solid tumors. Other applications include the use of retinal pigment epithelial cells for age-related macular degeneration (AMD) and insulin-secreting beta cells derived from iPSCs for Type 1 diabetes. These diverse therapeutic programs highlight the vast potential of iPSCs in treating a variety of diseases.
The commercial potential of iPSCs has also expanded significantly. Companies are leveraging iPSC-derived products in drug development, disease modeling, and toxicology testing. FUJIFILM Cellular Dynamics International (FCDI) stands out as one of the largest players in the field. Cellular Dynamics International (CDI), founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, became one of the first companies to derive human iPSC lines in 2007. In 2015, FUJIFILM acquired CDI for $307 million, creating FCDI, which is now the world’s largest producer of human cells derived from iPSCs for research and regenerative medicine.
ReproCELL, founded in 2009 as a venture from the University of Tokyo and Kyoto University, was the first company to commercialize iPSC products. Its ReproCardio line of iPSC-derived cardiomyocytes paved the way for the industry. In Europe, leading competitors include Evotec and Ncardia. Evotec, based in Hamburg, Germany, has built one of the most advanced iPSC platforms in the world, focusing on industrializing iPSC-based drug screening. Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017, specializes in cardiac and neural applications of iPSCs. Axiogenesis, one of its predecessors, was the first European company to license iPSC technology in 2010.
Large research supply companies are also playing a major role in the commercialization of iPSC-derived products. These include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and numerous others. Collectively, more than 90 companies are active in the iPSC market, offering a broad range of products, services, and technologies that cater to both research and therapeutic applications.
The global iPSC market continues to grow rapidly. A comprehensive report on the field provides an overview of key players, strategic partnerships, and innovations driving the sector. The report explores the current status of iPSC research, manufacturing technologies, and clinical developments. It highlights the rates of iPSC-related patents, publications, and trials, detailing all known therapeutic programs involving iPSC-derived cells. Additionally, the report covers the funding landscape, examining fundraising efforts, IPOs, and co-development agreements that are shaping the market’s trajectory.
The report also delves into the expanding use of iPSCs in drug discovery and the strategic partnerships that are driving growth in this sector. It presents a detailed breakdown of market size by application, technology, cell type, and geography (North America, Europe, Asia-Pacific, and the rest of the world). Total market size figures, along with projected growth rates through 2030, provide insights into the future of the iPSC industry.
With their remarkable versatility, iPSCs are set to redefine medicine and biotechnology. From disease modeling and drug discovery to advanced cell replacement therapies, iPSCs are driving innovation at every level. As companies continue to refine manufacturing technologies and expand therapeutic applications, the future of iPSCs holds immense promise for transforming healthcare and scientific research.
About the Publisher
With an online readership of nearly one million viewers per year, the publisher is a U.S. market research firm with over 18 years of experience. As the first and only market research firm to specialize in the stem cell industry, the publisher’s research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, the publisher is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, the publisher has unparalleled access to key opinion leaders (KOLs) from across the global iPSC market.
Table of Contents
389 Pages
- Statement of the Report
- Executive Summary
- INTRODUCTION
- Progress made in Autologous Cell Therapy using iPSCs
- Allogeneic iPSC-based Cell Therapies
- Share of iPSC-based Research within the Overall Stem Cell Industry
- Major Focus Areas of iPSC Companies
- Commercially Available iPSC-derived Cell Types
- Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
- iPSC-derived Cell Types used in Clinical Trials
- Currently Available iPSC Technologies
- Timeline of Important Milestones Reached in iPSC Industry
- First iPSC Generation from Mouse Fibroblasts, 2006
- First Human iPSC Generation, 2007
- Creation of CiRA, 2010
- First High-Throughput Screening using iPSCs, 2012
- First iPSC Clinical Trial Approved in Japan, 2013
- First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
- EBiSC Founded, 2014
- First Clinical Trial using Allogeneic iPSCs for AMD, 2017
- Clinical Trial for Parkinson's Disease using Allogeneic iPSCs, 2018
- Commercial iPSC Plant SMaRT Established, 2018
- First iPSC Therapy Center in Japan, 2019
- First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 2019
- Cynata Therapeutics' World's Largest Phase III Clinical Trial, 2020
- Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021
- Production of in-house iPSCs using Peripheral Blood Cells, 2022
- Global-First iPSC from Woolly Mammoth
- Rapid Growth in iPSC Publications
- iPSC Patent Applications by Jurisdiction
- iPSC Patent Applicants
- Inventors of iPSC Patents
- iPSC Patent Owners
- Legal Status of iPSC Patents
- Number of iPSC Clinical Trials
- Recruitment Status of iPSC Clinical Trials
- iPSC Clinical Trials Stydy Designs
- Therapeutic & Non-Therapeutic iPSC Clinical Trials
- iPSC-based Trials by Phase of Study
- iPSC Clinical Trials by Funder Type
- Geographic Distribution of iPSC-based Clinical Trials
- Promising iPSC Product Candidates
- Companies having Preclinical iPSC Assets
- Mergers and Acquisitions (M&A) Sector
- Partnership/Collaboration & Licensing Deals in iPSC Sector
- Venture Capital Funding in iPSC Sector
- OSKM Cocktail
- Pluripotency-Associated Transcription Factors and their Functions
- Delivery of Reprogramming Factors
- Genome Editing Technologies in iPSC Generation
- Available iPSC Lines and their applications
- Major Biobanks Storing iPSCs & iPSC Lines
- Cell Sources for iPSC Banks
- Reprogramming Methods in iPSC Banks
- Ownership and Investments made in iPSC Banks
- iPSCs in Basic Research
- Applications of iPSCs in Drug Discovery
- Applications of iPSCs in Toxicology Studies
- Applications of iPSCs in Disease Modeling
- Applications of iPSCs in Cell-Based Therapies
- Other Novel Applications of iPSCs
- Global Market for iPSCs by Geography
- Global Market for iPSCs by Technology
- Global Market for iPSCs by Biomedical Application
- Global Market for iPSCs by Derived Cell Type
- Market Drivers
- Market Restraints
- AcceGen
- Acellta, Ltd.
- AddGene, Inc.
- Allele Biotechnology, Inc.
- ALSTEM, Inc.
- Altos Labs
- AMS Biotechnology, Ltd. (AMSBIO)
- Applied StemCell (ASC)
- Asgard Therapeutics
- Aspen Neurosciences, Inc.
- Astellas Pharma, Inc.
- Axol Biosciences, Ltd.
- BioCentriq
- Bit.bio
- BlueRock Therapeutics LP
- BrainXell
- Cartherics Pty, Ltd.
- Catalent Biologics
- Cellistic
- CellOrigin Biotech (Hangzhou), Co., Ltd.
- Celogics, Inc.
- Cellular Engineering Technologies (CET)
- Cellusion, Inc.
- Century Therapeutics, Inc.
- Citius Pharmaceuticals, Inc.
- Creative Bioarray
- Curi Bio
- Cynata Therapeutics, Ltd.
- Cytovia Therapeutics
- DefiniGEN
- Editas Medicine
- Editco Bio., Inc.
- ElevateBio
- Elixirgen Scientific, Inc.
- Eterna Therapeutics
- Evotec AG
- Eyestem
- Fate Therapeutics
- FUJIFILM Cellular Dynamics, Inc.
- Gameto
- Greenstone Biosciences
- Heartseed, Inc.
- HebeCell
- Helios K.K.
- Hera BioLabs
- Hopstem Biotechnology
- Implant Therapeutics, Inc.
- IN8bio
- I Peace, Inc.
- IPS HEART
- iPS Portal, Inc.
- iPSirius
- iXCells Biotechnologies
- Kenai Therapeutics, Inc.
- Khloris Biosciences, Inc.
- Kytopen
- Laverock Therapeutics
- Lindville Bio, Ltd.
- Lonza Group, Ltd.
- Matricelf
- Megakaryon Corporation
- Metrion Biosciences, Ltd.
- Mogrify
- Ncardia Services B.V.
- NeuCyte
- Neukio Biotherapeutics
- Newcells Biotech
- NEXEL, Co., Ltd.
- Notch Therapeutics
- Orizuru Therapeutics, Inc.
- Phenocell SAS
- Pluristyx
- ReNeuron
- Repairon GmbH
- REPROCELL USA, Inc.
- Res Nova Bio, Inc.
- Sartorius CellGenix GmbH
- Shinobi Therapeutics
- Shoreline Biosciences
- StemSight
- Stemson Therapeutics
- Stemina Biomarker Discovery
- Tempo Bioscience, Inc.
- Uncommon (Higher Steaks)
- Universal Cells
- VCCT, Inc.
- ViaCyte, Inc.
- Vita Therapeutics
- XCell Science
- Yashraj Biotechnology, Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.